ETCAMAH (Camizestrant)

ETCAMAH (camizestrant), from AstraZeneca, is an oral selective oestrogen receptor degrader (SERD). The FDA granted accelerated approval on 4 September 2026 for use with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) in adults with HR-positive, HER2-negative advanced breast cancer whose tumours develop an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy — detected by a ctDNA blood test (Guardant360 CDx) before scans show progression.

Camizestrant blocks and degrades the oestrogen receptor, including mutated forms that make aromatase inhibitors stop working. In the Phase 3 SERENA-6 trial, switching to camizestrant when an ESR1 mutation appeared extended median progression-free survival to 16.0 months versus 9.2 months with continued aromatase inhibitor. The FDA called it the first cancer approval guided by a resistance mutation found in circulating tumour DNA.

• Bradycardia (slow heart rate) can occur; heart rate should be monitored more often in the first 30 days, and other drugs that slow the heart avoided.
• ETCAMAH can harm an unborn baby; effective contraception is required.
• Common side effects with a CDK4/6 inhibitor include low blood counts, visual disturbances and fatigue. Continued US approval may depend on confirmatory data.

What documents are required to import ETCAMAH to India?

ETCAMAH may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered medical oncologist
• Histopathology (HR/HER2 status) and ctDNA report showing an ESR1 mutation
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is ETCAMAH available in India?

ETCAMAH is not available in India. It can be legally accessed through the Named Patient Program (NPP), subject to applicable regulations.

Indian Pharma Network (IPN) can source ETCAMAH from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For ETCAMAH cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA accelerated approval — 4 September 2026.
• European Union: Approved — 2026.
• Japan: Approved — 19 June 2026.

What is ETCAMAH used for?

ETCAMAH (camizestrant) is a next-generation oral SERD used for ESR1-mutated HR+/HER2- advanced breast cancer.

Who manufactures ETCAMAH?

ETCAMAH is from AstraZeneca.

How does ETCAMAH work?

Camizestrant blocks and degrades the oestrogen receptor, including mutated forms that make aromatase inhibitors stop working.

Do patients need a special test before ETCAMAH?

Yes. An ESR1 mutation must be detected in circulating tumour DNA, using the FDA-approved Guardant360 CDx blood test.

Is ETCAMAH approved by the US FDA?

Yes. The FDA granted accelerated approval on 4 September 2026.